Clinical Trial
Search documents
Gossamer Bio (GOSS) Earnings Call Presentation
2025-07-04 14:12
Seralutinib Partnership with Chiesi - Chiesi will provide a $160 million immediate development reimbursement to Gossamer[13] - Gossamer and Chiesi will split US profits 50/50, with mid-to-high teens royalties to Gossamer ex-US[13] - Regulatory milestones could reach up to $146 million, and sales milestones up to $180 million[13] - R&D costs will be split 50/50 worldwide, with Gossamer leading global development and US commercialization of PAH & PH-ILD[13] - Gossamer has a pro forma cash position of approximately $396 million[20, 38] Seralutinib in PAH - Seralutinib is in an ongoing registrational Phase 3 trial for PAH, with topline results expected in Q4 2025[13, 24, 26] - The PROSERA Phase 3 study is a double-blind, placebo-controlled trial with 175 patients per arm[26] - The US has approximately 30,000 to 50,000 PAH patients, with a 5-year survival rate of 57%[13, 22, 23, 35] Seralutinib in PH-ILD - The US has approximately 60,000 to 100,000 PH-ILD patients[13, 29, 35] - The median 5-year survival for PH-ILD patients is 23%[13, 35] - A Phase 3 study in PH-ILD is expected to begin in mid-2025[13, 20] - Only one therapy is approved for PH-ILD in the US[29, 30, 35]
Could digital twins – virtual replicas of humans or organs – accelerate medical research? 🏥
Google DeepMind· 2025-07-03 11:17
Digital twins is quite a big hot topic at the moment. Is there an idea of making a kind of digital twin of yourself for healthcare purposes. Yeah, we see that a lot and it can mean different things for different people.For the pharma industry, for example, where there's a lot of work trying to see how far we can go with clinical trials, if we manage to assemble uh virtual cohorts that are allowing us to in the end gain as much knowledge about the safety and efficacy of a drug, but without needing as many pe ...
2 Beaten-Down Stocks With Massive Upside Potential
The Motley Fool· 2025-07-03 11:00
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 4.01%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.Even with these poor performances, however, there are solid reasons to consider investing in these stocks, especially at current levels. Read on to find out more. 1. CRIS ...
高盛：全球医疗保-2025 年第三季度值得关注的生物制药催化因素
Goldman Sachs· 2025-07-03 02:41
Global Healthcare Biopharma catalysts to watch in 3Q25 With macroeconomic volatility and healthcare policy uncertainty persisting likely into the back half of the year, we continue to advocate for and highlight idiosyncratic catalysts with attractive risk/reward setups to drive alpha generation. Herein, we highlight and preview key catalysts in 3Q25 across the GS biotechnology coverage universe from pivotal studies: BMY's Cobenfy ADEPT-2 in Alzheimer's disease psychosis; LLY's orforglipron ATTAIN-1 in obesi ...